Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
69.6M
-
Number of holders
-
85
-
Total 13F shares, excl. options
-
30.1M
-
Shares change
-
+2.99M
-
Total reported value, excl. options
-
$333M
-
Value change
-
+$38.5M
-
Number of buys
-
47
-
Number of sells
-
-36
-
Price
-
$11.08
Significant Holders of Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT) as of Q3 2022
104 filings reported holding PHAT - Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q3 2022.
Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT) has 85 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.1M shares
of 69.6M outstanding shares and own 43.24% of the company stock.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (8.41M shares), Medicxi Ventures Management (Jersey) Ltd (2.48M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2.41M shares), Invesco Ltd. (2.07M shares), Avidity Partners Management LP (1.91M shares), Ensign Peak Advisors, Inc (1.76M shares), 683 Capital Management, LLC (1.66M shares), BlackRock Inc. (1.54M shares), Abingworth LLP (1.44M shares), and VANGUARD GROUP INC (970K shares).
This table shows the top 85 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.